Exagen Inc (XGN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $105.37M
Last updated: Nov 17, 2026 at 11:06 AM ET
Exagen Inc (XGN) Stock Forecast
Analysts expect Exagen (XGN) to earn -$0.73 per share in the fiscal year ending Dec 31, 2026, on revenue of $73.74M. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 7 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 9.5%.
- Fiscal year ending Dec 31, 2026
- -$0.73
- EPS consensus, revenue $73.74M
- Fiscal year ending Dec 31, 2027
- -$0.50
- EPS consensus, revenue $80.77M
- Next report
- Mar 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.73 | -$0.75 to -$0.71 | 2 | $73.74M | $72.70M to $74.20M | 7 |
| Dec 31, 2027 | -$0.50 | -$0.57 to -$0.40 | 3 | $80.77M | $79.10M to $82.30M | 6 |
Quarterly Estimates
The EPS consensus rises from -$0.19 for the quarter ending Dec 31, 2026 to -$0.17 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.19 | -$0.21 to -$0.17 | 9 | $18.25M | $16.76M to $19.43M | 9 |
| Mar 31, 2027 | -$0.17 | -$0.19 to -$0.14 | 3 | $18.42M | $17.80M to $18.90M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.62.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.73 | -$0.63 | -$0.62 | -$0.62 | -$0.62 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.50 | -$0.47 | -$0.47 | -$0.47 | -$0.44 | N/A |
| Quarter ending Mar 31, 2027 | -$0.17 | -$0.16 | -$0.16 | -$0.16 | -$0.15 | N/A |
Frequently Asked Questions About XGN
What is the XGN stock forecast?
Consensus analyst estimates put Exagen's EPS at -$0.73 for the fiscal year ending Dec 31, 2026, on revenue of $73.74M. The consensus rating from 7 analysts is Buy.
How do analysts rate XGN stock?
Of 7 analysts covering Exagen, 0 rate it Strong Buy, 7 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from XGN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.73, with estimates from -$0.75 to -$0.71 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.50, with estimates from -$0.57 to -$0.40 from 3 analysts.
What revenue do analysts expect from Exagen next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $73.74M, with estimates from $72.70M to $74.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $80.77M, with estimates from $79.10M to $82.30M.
How many analysts cover XGN?
7 analysts rate Exagen stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
XGN pages: Overview, Earnings, Forecast, Financials, Competitors